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ABSTRACT: The aryl hydantoin 1 (Ro 13-3978) was identiﬁed in the early 1980s as a promising antischistosomal lead
compound. However, this series of aryl hydantoins produced antiandrogenic side eﬀects in the host, a not unexpected outcome
given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series,
we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and
functional groups known to diminish ligand−androgen receptor interactions. These analogs had calculated polar surface area
(PSA), measured LogD7.4, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good
ADME proﬁles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We
identiﬁed several compounds with high antischistosomal eﬃcacy that were less antiandrogenic than 1. These data provide
direction for the ongoing optimization of antischistosomal hydantoins.
Schistosomiasis is a tropical parasitic disease caused byinfections with ﬂukes of the genus Schistosoma.1 Of these,
Schistosoma mansoni, S. hematobium, and S. japonicum cause the
largest public health burden.2,3 Praziquantel (PZ) is the only
drug available for treatment of this disease.4−6 The high drug
pressure from the widespread administration of PZ could lead
to problematic drug resistance.7,8 Even so, the discovery of a
new drug for schistosomiasis continues to elude us, although
several antischistosomal lead compounds and repurposed drugs
have been identiﬁed in recent years.9−14
The introduction of PZ in 1982 likely led to decisions to
abandon the development of a number of promising
antischistosomal agents that were discovered during the same
time period. One of these was 1 (Ro 13-3978) (Figure 1), the
lead compound from a series of aryl hydantoins that were
investigated in some detail at Hoﬀmann La-Roche.15−18 As
reported by Link and Stohler,18 1 has high oral eﬃcacy against
all three major schistosome speciesS. mansoni, S. hematobium,
and S. japonicumin a range of animal models. Conﬁrming
these data, we found that 1 had single oral dose ED50 values of
15 and 140 mg/kg against adult and juvenile S. mansoni in a
mouse model.19 In this same schistosome mouse model, PZ is
considerably less eﬀective against adult S. mansoni, with
reported ED50 values ranging from 172 to 202 mg/kg,
18,20
and it has no signiﬁcant activity against juvenile stages of the
parasite. Despite the high in vivo antischistosomal eﬃcacy of 1,
we found that this aryl hydantoin at concentrations up to 170
μM had almost no eﬀect on adult S. mansoni in vitro.19 Data
generated so far indicate that active metabolites do not account
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for the striking diﬀerence between the in vitro and in vivo
antischistosomal activity of 1.19
However, this series of aryl hydantoins produced antiandro-
genic side eﬀects in the host,15 a not unexpected outcome given
their close structural similarity to the antiandrogenic drug
nilutamide (N). We recently demonstrated that N, but not the
three structurally diverse androgen receptor (AR) antagonists
ﬂutamide, bicalutamide, and cyproterone acetate, has weak, but
measurable, antischistosomal activity in S. mansoni-infected
mice.21 As phylogenetic evidence indicates that schistosome
species do not appear to have AR’s,22 these data led us to
hypothesize that, for aryl hydantoins and related heterocycles,
the structural requirements for antischistosomal eﬃcacy and
AR binding interactions are divergent. In this respect, 1 had no
measurable interaction with the AR in a ligand competition
assay, but it did block DHT-induced cell proliferation in an
androgen-dependent cell line.23 Despite its antiandrogenic
liability, Link and Stohler18 observed no apparent toxicity
following administration of a single 1250 mg/kg dose of 1 to
mice.
Highlights from the SAR of this aryl hydantoin compound
series conducted by Hoﬀmann La-Roche18 are (1) a
combination of halogens (F, Cl) and/or CF3 groups at
positions 3 and 4 of the phenyl ring was optimal; (2)
electron-donating groups such as methoxy and dimethylamino
at these same positions diminished activity; (3) 4-imino
derivatives were active; and (4) some N1-substituted analogs
were active. Building on this foundation, we now describe a
number of analogs of 1 (2−36, Tables 1−4) designed to
maximize structural diversity guided by incorporation of
substructures and functional groups known to diminish
ligand−AR interactions. For example, several target compounds
maintain the 5,5-dimethylhydantoin core of 1 and incorporate
phenethyl (6), sulfonamide (7, 8), aromatic halogens (10), and
CN bonds (15−20), functional groups and structural
elements demonstrated to abolish or diminish AR ligand
aﬃnity.24−28 The ﬁnal set of target compounds maintains the 4-
ﬂuoro-3-triﬂuoromethylphenyl substructure of 1 in heterocycle
variants of the 5,5-dimethylhydantoin substructure: succinimide
29, oxazolidinedione 30, oxolactam 31, urea 32, hydantoin
transpositional isomer 33, and the ring-expanded dihydropyr-
imidinediones 34 and 35. Hydantoins analogous to 33 had
relatively weak AR binding aﬃnity.24 We now report
physicochemical proﬁling, in vitro ADME, antiandrogenic
assessment, plasma exposure, and in vivo antischistosomal
activities of these compounds.
■ CHEMISTRY
N1-Alkyl and aralkyl hydantoins 2−6 and sulfonamides 7 and 8
were obtained by N-alkylation and sulfonylation of 1 according
to the methods of Van Dort and Jung28 and Jung et al.24
(Scheme 1). Urea carboxylic acid 36 was obtained in high yield
by hydrolysis of 1 with aqueous NaOH followed by
acidiﬁcation with dilute HCl.
Target compounds 11−13, 16, 17, 19, and 20 were obtained
in variable yields by high-temperature reactions of the
corresponding aryl iodides (37−41, 43, and 44) and hyantoin
42 with cuprous oxide29,30 in dimethylacetamide (DMA)
(Scheme 2).
Reactions between aryl iodide 45 and spiro hydantoin 46 or
succinimide 47 under these same conditions aﬀorded 27 and
29, respectively (Scheme 3). Similarly, 14 was obtained by
copper-catalyzed coupling of aryl bromide 49 and 42, whereas
21 was obtained by alkylation of benzyl bromide 50 with 42
(Scheme 4). Compound 32 was obtained in a palladium-
catalyzed N-arylation reaction31 between aryl iodide 45 and
imidazolidin-2-one 4832 (Scheme 3).
N-Arylation via copper(II) acetate promoted cross-cou-
pling33−35 of boronic acids 51 and 52 with 42 aﬀorded 18
and 15; the same cross-coupling reaction between boronic acid
53 and 1,3-oxazolidine-2,4-dione 54 or bicyclic hydantoin 55
aﬀorded 30 and 28, respectively (Scheme 5).
Scheme 1a
aReagents and conditions: (a) NaH, DMF, rt, 0.5 h, then MeI, rt, 2 h;
(b) NaH, THF, 0 °C to rt, 0.5 h, then EtI, rt, 3 d; (c) NaH, THF, 0 °C
to rt, 0.5 h, then 2-bromoacetamide, rt, 3 d; (d) NaH, DMF, rt, 0.5 h,
then 2-bromoacetonitrile, rt, 2 h; (e) NaH, DMF, rt, 0.5 h, then 2-
bromoethylbenzene, rt, 2 h; (f) NaH, THF, 0 °C to rt, 0.5 h, then
MeSO2Cl, rt, 3 d; (g) NaH, DMF, rt, 0.5 h, then benzenesulfonyl
chloride, rt, 2 h; (h) 2 M NaOH, rt, 4 h, then 2 M HCl.
Scheme 2a
aReagents and conditions: (a) Cu2O, DMA, 140−160 °C; 12−72 h.
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Compounds 23−26 were obtained in a two-step se-
quence18,27,36 by reactions between aryl isocyanate 56 and α-
amino acids 57−60 in aqueous NaOH to form the
corresponding urea carboxylic acids that then cyclized to the
hydantoins when exposed to 2−4 M HCl at 110 °C (Scheme
6). Compounds 34 and 35 were obtained by parallel two-step
reactions between 56 and β-amino acids 61 and 62. In some
instances, the acyclic urea carboxylic acid reaction intermediates
precipitated from the initial reactions after acidiﬁcation, but
these were not usually puriﬁed, and were converted directly to
the desired hydantoin reaction products. For almost all of these
reactions, small amounts of the insoluble symmetrical N,N-
diarylurea derived from isocyanate 56 were formed.
Oxolactam 31 was obtained by cyclization of the anion of
benzyl amide ester 66 in a Dieckmann-type condensation;37 66
was obtained from the corresponding acid chloride 65 (Scheme
7). The key intermediate in the synthesis of 33 was gem-
dimethyl α-amino amide 64, which was obtained in a one-pot
Scheme 3a
aReagents and conditions: (a) Cu2O, DMA, 160 °C; 24 h; (b) Cu2O,
DMF, 160 °C; 48 h (29); (c) Pd2(dba)3, Xanthphos, Cs2CO3, toluene,
90 °C; 12 h (32).
Scheme 4a
aReagents and conditions: (a) Cu2O, DMA, 160 °C, 24 h; (b) K2CO3,
DMA, 85 °C; 24 h.
Scheme 5a
aReagents and conditions: (a) Cu(OAc)2, MeOH, O2, 70 °C; 12 h;
(b) Cu(OAc)2, pyridine, CH2Cl2, rt, 7 d.
Scheme 6a
aReagents and conditions: (a) 1−2 M NaOH, 0 °C to rt, 3−12 h; (b)
2−4 M HCl, 110 °C, 2−12 h.
Scheme 7a
aReagents and conditions: (a) 1 M TiCl4 in CH2Cl2, formamide,
acetone, CH2Cl2, 0 °C, 0.5 h, then Zn, 50% H2O2 in formamide, 0 °C,
3 h; (b) 2,6-diisopropylphenyl isocyanate, toluene, 250 °C, 5 bar, 10
min, MW; (c) methyl 2-amino-2-methylpropanoate HCl, Et3N, THF,
rt, 12 h; (d) NaH, THF, rt, 12 h, then aq AcOH.
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free radical multicomponent reaction38 from aniline 63.
Exposure of 64 to 2,6-diisopropylphenyl isocyanate at high
temperature39 eﬀected carbonylative ring closure to hydantoin
33. Compounds 1, 9, 10, and 22 were synthesized following
procedures described by Link et al.18
■ PHYSICOCHEMICAL AND IN VITRO ADME
It is instructive to ﬁrst consider the physicochemical and in
vitro ADME properties of these analogs of 1 (Tables 1−4). The
calculated polar surface area (PSA) values of between 32 and 84
Å2 indicate that the polarity of these compounds is unlikely to
be a rate-limiting factor for membrane permeability and oral
bioavailability.40 The measured LogD7.4 values for all but two of
the compounds ranged from 0 to 4, suggesting that high
lipophilicity and the resulting poor aqueous solubility are
unlikely to be limiting factors for oral absorption; this was
largely borne out by the fairly high aqueous kinetic solubilities
of many of these compounds. Compounds with low solubilities
Table 1. Physicochemical, in Vitro ADME, Antiandrogenic, and Antischistosomal Data for N1-Substituted 4-Fluoro-3-
triﬂuoromethylphenyl Hydantoins
Compd R LogD7.4
a
PSA
(Å2)b
cPPB
(%)c
Sol2.0/Sol6.5
(μg/mL)d
h/m CLint (μL/min/mg
protein)e
LAPC4
IC50 (μM)
f
S. mansoni WBR (%) 1 × 100
mg/kg pog
1 H 2.7 49.4 52.1 >100/>100 8/<7 4.4 95h
2 CH3 3.2 40.6 40.9 50−100/50−100 16/65 1.3 93*
3 CH2CH3 3.5 40.6 49.3 50−100/25−50 30/32 0.14 98*
4 CH2CONH2 2.2 83.7 20.3 50−100/50−100 <7/<7 agonist 25
5 CH2CN 3.4 64.4 48.2 25−50/25−50 NDj 0.29 91*
6 (CH2)2C6H5 4.6 40.6 96.2 12.5−25/25−50 >870/740 2.4 54
7 SO2CH3 3.8 74.8 66.0 1.6−3.1/1.6−3.1 <7/<7 6.3 19
8 SO2C6H5 4.6 74.8 96.1 <1.6/<1.6 210/160 4.3 44
PZ 3.0 40.6 ND >100/>100 52/790 ND 18i
aLogD values were estimated by correlation of their chromatographic retention properties using gradient HPLC.46 bCalculated using ChemAxon
JChem for Excel. cProtein binding values were estimated by correlation of their chromatographic retention properties on a human albumin column.47
dCompounds in DMSO were spiked into either pH 6.5 phosphate buﬀer or 0.01 M HCl (approximately pH 2.0) and analyzed by nephelometry to
determine a concentration range. eIn vitro intrinsic clearance measured in human and mouse liver microsomes. fCells were then exposed to 10 nM
DHT for 24 h in the presence of varying concentrations of test compounds. gGroups of ﬁve S. mansoni-infected NMRI mice were treated on day 49
postinfection with compounds dissolved or suspended in 7% v/v Tween 80, 3% v/v ethanol. At 28 d post-treatment, animals were sacriﬁced and
dissected to assess total worm burden reduction (WBR). *p < 0.05 from the Kruskal−Wallis test comparing the medians of the responses between
the treatment and control groups. hData from Keiser et al.19 iData from Keiser et al.21 jND = not determined.
Table 2. Physicochemical, in Vitro ADME, Antiandrogenic, and Antischistosomal Data for N3-Substituted Aryl Hydantoins
Compd LogD7.4 PSA (Å
2)
cPPB
(%)
Sol2.0/Sol6.5
(μg/mL)
h/m CLint (μL/min/mg
protein)
LAPC4 IC50
(μM) S. mansoni WBR (%) 1 × 100 mg/kg po
N 3.0 92.6 70.3 50−100/50−100 <7/<7 0.60/0.45 31a
9 2.5 49.4 49.3 >100/>100 <7/<7 6.0 80*
10 3.0 49.4 79.6 >100/>100 <7/<7 1.3 75*b
11 2.8 49.4 64.8 >100/>100 <7/16 >10 4.8
12 1.7 73.2 14.6 >100/>100 <7/<7 3.7 10
13 0.9 69.7 5.9 >100/>100 <7/<7 9.1 30
14 2.2 49.4 20.4 >100/>100 <7/<7 ≥10 94*
15 0.5 62.3 6.7 50−100/>100 <7/11 3.8 1.8
16 1.9 62.3 22.7 >100/>100 <7/<7 4.5 100*
17 1.2 62.3 16.9 >100/>100 <7/<7 1.3 17
18 0.2 62.3 6.6 >100/>100 <7/<7 9.6 38
19 1.8 62.3 18.3 >100/>100 <7/<7 >10 0
20 0.3 75.2 5.8 >100/>100 <7/<7 >10 42
21 2.9 49.4 82.1 50−100/>100 17/11 4.2 56*
aData from Keiser et al.21 b1/4 mice died.
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were sulfonamides 7 and 8, 5-phenylhydantoin 24, 5,5-
spirocyclopentylhydantoin 27, and 1,3-oxazolidine-2,4-dione
30.
The only compounds with estimated plasma protein binding
values ≥90% were aryl sulfonamide 8, N1-phenethyl 6, 5-phenyl
24, oxolactam imide 31, and urea carboxylic acid 36. Notably,
these compounds featured either additional aryl substructures
(6, 8, 24) or weak acid functional groups (31 and 36). In this
respect, we note that 1, with its pKa value of 12.1,
17 is largely
un-ionized at physiological pH. The metabolic stabilities of the
N1-alkyl and N1-sulfonamide hydantoin derivatives (Table 1)
varied from highly stable (7), to intermediate (2, 3), to unstable
(6, 8). For N1-alkyl hydantoins 2 and 3 we observed N-
dealkylation metabolic reactions to form 1. Notably, 6 and 8,
with their additional aryl groups, were the most lipophilic
members of the series and also had the lowest metabolic
stabilities. However, as seen for carboxamide 4, addition of
polar functional groups in the N1-alkyl substructure can
increase metabolic stability. The N3-aryl hydantoins (Table 2)
and hydantoin heterocycle variants (Table 4) had high
metabolic stabilities. Hydantoins substituted at the 5 position
(Table 3) with combinations of methyl, hydrogen, and
hydroxymethyl (1, 22, 23, 25) had high metabolic stabilities.
However, incorporation of aryl (24) or spirocycloalkyl (26, 27)
substructures, or linking the 5 and N1 positions by way of a
pyrrolidine heterocycle (28), decreased the metabolic stabil-
ities.
■ ANTIANDROGENIC AND ANTISCHISTOSOMAL
ACTIVITIES
We now consider the in vitro antiandrogenic and in vivo
antischistosomal properties of these analogs of 1. The former
was assessed by inhibition of dihydrotestosterone (DHT)-
induced androgen luciferase reporter activity in the LAPC4 cell
line, a cell line with a wild-type androgen receptor (AR), and
the latter by measuring worm burden reduction (WBR) in S.
mansoni-infected mice. As we had previously observed for 1,
none of the compounds at concentrations up to 100 μM had
activity against schistosomula or adult S. mansoni in vitro.
Similarly, none of the compounds was cytotoxic at concen-
trations up to 30 μM against the rat skeletal myoblast L6 cell
line. Contrary to our expectation based on the previous SAR for
this compound class, we did not observe decreased
antiandrogenic potencies for N1-substituted sulfonamides 7
and 8 or N1-phenethyl 6 (Table 1). N1-Substitution with small
alkyl (2, 3) groups increased antiandrogenic potencies, most
Table 3. Physicochemical, in Vitro ADME, Antiandrogenic, and Antischistosomal Data for 5-Substituted 4-Fluoro-3-
triﬂuoromethylphenyl Hydantoins
Compd X, Y LogD7.4
PSA
(Å2)
cPPB
(%) Sol2.0/Sol6.5 (μg/mL)
h/m CLint (μL/min/mg
protein)
LAPC4 IC50
(μM)
S. mansoni WBR (%) 1 × 100
mg/kg po
22 H, H 2.0 49.4 43.6 >100/>100 <7/13 0.26 0
23 CH3, H 2.4 49.4 38.6 >100/>100 17/34 >10 66*
24 C6H5, H 3.5 49.4 90.0 6.3−12.5/6.3−12.5 22/181 5.3 41
25 CH3,
CH2OH
1.9 69.6 34.3 25−50/25−50 <7/<7 4.8 0
26 (CH2)4 3.2 49.4 70.4 50−100/50−100 33/93 0.99 61
27 (CH2)5 3.5 49.4 74.9 3.1−6.3/3.1−6.3 25/122 4.2 42
28 3.0 40.6 46.0 25−50/25−50 30/144 3.5 0
Table 4. Physicochemical, in Vitro ADME, Antiandrogenic, and Antischistosomal Data for 4-Fluoro-3-triﬂuoromethylphenyl
Hydantoin Heterocyle Variants
Compd LogD7.4
PSA
(Å2)
cPPB
(%) Sol2.0/Sol6.5 (μg/mL)
h/m CLint (μL/min/mg
protein)
LAPC4 IC50
(μM) S. mansoni WBR (%) 1 × 100 mg/kg po
29 3.4 37.4 42.5 12.5−25/12.5−25 11/10 0.91 42
30 3.7 49.6 58.1 3.1−6.3/3.1−6.3 12/12a 2.1 11
31 0.5 46.2 93.3 25−50/>100 <7/<7 >10 0
32 3.2 32.3 78.3 12.5−25/12.5−25 <7/30 8.1 59
33 2.5 49.4 67.1 25−50/25−50 <7/<7 2.8 0
34 2.4 49.4 15.0 25−50/25−50 <7/<7 >10 51b
35 2.5 49.4 21.5 12.5−25/12.5−25 9/15 6.9 19
36 1.1 81.3 94.3 25−50/>100 <7/<7 3.1 67
anon-NADPH-mediated degradation observed. b2/4 mice died.
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strongly for the latter. Incorporation of nitrile (5) and
carboxamide (4) functional groups into the N1-alkyl sub-
structure had very diﬀerent eﬀects; the former was a potent
antiandrogen whereas the latter had no antiandrogenic
properties and was instead a weak AR agonist. It is known41
that hydantoins with N1-cyanomethyl substructures are potent
antiandrogens; thus, 5 served as a “negative control compound”
for this SAR study. Similar to that of 1, N1-substituted
hydantoins 2, 3, and 5 had high antischistosomal activities; of
the remaining compounds in this series, 6 had weak
antischistosomal activity.
The antiandrogenic and antischistosomal properties of the
N3-substituted aryl hydantoins exhibit several interesting trends
(Table 2). Replacing the 4-F in 1 with a NO2 (N) or Cl (10)
increased antiandrogenic potency, whereas a H (9) or Me (11)
at this same position decreased antiandrogenic potency. Of
these, hydantoins 9 and 10 had high antischistosomal activities,
similar to previously reported data.18 Replacing the 3-triﬂuoro
in 1 with a nitrile (12) had no eﬀect on antiandrogenic potency
and abolished antischistosomal activity. However, replacing the
3-triﬂuoro in 1 with a tertiary carboxamide (13) or
diﬂuoromethyl (14) decreased antiandrogenic potency, and
the latter had high antischistosomal activity. Hydantoin 21, the
benzyl derivative of 1, had similar antiandrogenic potency but
substantially reduced antischistosomal activity compared to the
latter. As we had anticipated based on the known SAR for
antiandrogenic hydantoins, we observed decreased antiandro-
genic potencies for some of the derivatives with aromatic CN
bonds; these included pyridines 18 and 19 and pyrazine 20.
However, the only one of the CN containing hydantoins to
have high activity against S. mansoni in vivo was 16, the 4-
pyridyl derivative with a triﬂuoromethyl group, which at 100
mg/kg resulted in cure of all of the infected mice.
As the data in Table 3 illustrate, our initial foray into the SAR
of the 5-position of 1 did not bear much fruit. The principle
insight gained was to note that removing one, but not both, of
the methyl groups (23) decreases antiandrogenic activity and
retains signiﬁcant antischistosomal activity. 5,5-Spirocycloalkyl
derivatives 26 and 27 had measurable but insigniﬁcant worm
burden reduction (WBR) values and were no less antiandro-
genic than 1. Bicyclic hydantoin 28 reveals that connecting the
5- and N1-positions with a pyrrolidine substructure completely
abolished antischistosomal activity and oﬀered no improvement
in antiandrogenic activity. Finally, the data in Table 4 shows
that the hydantoin core of 1 is required for high
antischistosomal eﬃcacy. Of these, only cyclic urea 32 and
urea carboxylic acid 36 had moderate antischistosomal
activities. The latter is the hydrolysis product of 1 and is
formed in small quantities when 1 is administered at high doses
(vide inf ra, Figure 2a). Interestingly, as reported by Link and
Stohler,18 the methyl ester of 36, with a single-dose ED50 of 62
mg/kg, has signiﬁcant antischistosomal activity.
■ MOUSE EXPOSURE
With this compound series, we have the unusual situation
where lead compounds have no in vitro activity but generally
exhibit in vivo activity. Therefore, to see if there was a
correlation between antischistosomal eﬃcacy and plasma
exposure and to begin to assess the eﬀect of aryl hydantoin
structure on pharmacokinetics, the most active aryl hydantoins
(1−3, 14, and 16) and three less active hydantoins (13, 23, 26)
were administered to noninfected mice at single oral doses of
100 mg/kg. From a practical standpoint, it was necessary to
assume that exposure proﬁles generated in noninfected mice
provided a reasonable estimation of exposure in S. mansoni-
infected mice.
After oral administration of 1, plasma concentrations
increased until 2 h postdose, after which concentrations
remained relatively constant up to 24 h, most likely due to
saturated clearance processes at the very high concentrations
(Figure 2A, Table 5). We also observed low but measurable
concentrations of urea carboxylic acid 36, the hydantoin
hydrolysis product, and 25, the hydroxymethyl metabolite.
Based on values for AUC0−24h, the exposures of 36 and 25 were
<1% and approximately 3%, respectively, relative to 1.
Following oral administration of 2 or 3 (Figure 2B and 2C),
concentrations of the parent compounds rapidly declined with
subsequent formation of 1 at maximum concentrations
comparable to that seen following dosing with 1 (Figure 2A).
Hydantoins 13, 14, 16, 23, and 26 were all rapidly absorbed;
however, they diﬀered substantially in their plasma exposure
proﬁles. The highest and most prolonged exposures were
Figure 2. Plasma concentration versus time proﬁles of (A) 1 (ﬁlled
triangles) and the metabolites 36 (ﬁlled circles) and 25 (open
diamonds); (B) 2 (open circles) and the metabolite 1 (ﬁlled
triangles); and (C) 3 (open circles) and the metabolite 1 (ﬁlled
triangles) following oral administration of 100 mg/kg to male Swiss
outbred mice. Symbols represent individual data points, and the lines
represent the mean proﬁles.
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observed for 14 and 16, where plasma concentrations were
comparable to those for 1 (Figure 3A and Table 5). Both the
maximum concentrations and the duration of exposures of 23
and 26 were substantially lower, likely due in part to their
higher intrinsic clearance, as determined in mouse microsomes
(Figure 3B and Table 5). While 13 reached a higher maximum
plasma concentration than either 14 or 16, concentrations
declined at a much faster rate, resulting in a considerably
reduced duration of exposure (Figure 3B and Table 5). As 13
had a low intrinsic clearance in mouse microsomes, its more
rapid rate of elimination is likely due to its lower log D value
(0.9), resulting in a lower volume of distribution and, possibly,
signiﬁcant renal excretion.
■ SUMMARY
Hydantoin 1 and its analogs 2−36 had calculated polar surface
area (PSA), measured LogD7.4, aqueous kinetic solubility, and
estimated plasma protein binding values in ranges predictive of
good ADME proﬁles. For N1-alkyl and N1-sulfonamide
derivatives of 1, incorporation of polar functional groups
increased metabolic stability, whereas incorporation of phenyl
substructures decreased metabolic stability. However, none of
these possessed both decreased antiandrogenic potency and
increased antischistosomal activity. N3-Aryl hydantoins, hydan-
toin heterocycle variants, and hydantoins substituted at the 5
position with combinations of methyl, hydrogen, and
hydroxymethyl had high metabolic stabilities. The SAR of the
N3-substituted aryl hydantoins was complex, but three of these
had high antischistosomal eﬃcacy and were less antiandrogenic
than 1. The SAR of the 5-substituted aryl hydantoins reveals
that replacing one of the methyl groups with a hydrogen atom
decreases antiandrogenic activity and retains signiﬁcant
antischistosomal activity. Investigation of heterocycle variants
showed that the hydantoin core of 1 is required for high
antischistosomal activity. In this respect, recent investigations of
a series of structurally distinct 4-thiohydantoins reveal that they
have activity against S. mansoni in vitro;42 the best of these
eﬀected a 71% worm burden reduction (WBR) in S. mansoni-
infected mice when it was administered as ﬁve daily 100 mg/kg
oral doses.43
Exposure data for selected compounds reveals the following.
First, N1-alkyl hydantoins 2 and 3 had high antischistosomal
activities, due most likely to their extensive conversion to 1 by
metabolic N-dealkylation reactions. Second, N3-aryl hydantoins
14 and 16, two of the most active compounds, had, like 1, high
plasma exposures; conversely, N3-aryl hydantoin 13, 5-methyl
hydantoin 23, and 5,5-dispirocyclopentyl hydantoin 26, three
less eﬀective compounds, had relatively low plasma exposures.
These data are suggestive that antischistosomal eﬃcacy and
plasma exposure may correlate. This study provides several
insights for the ongoing identiﬁcation of more eﬀective
antischistosomal hydantoins.
■ EXPERIMENTAL SECTION
General. All reagents were purchased from Sigma-Aldrich, Fisher,
or Acros Organics and used without further puriﬁcation, unless
otherwise stated. Melting points were determined with a Stanford
Research Systems melting point apparatus and are uncorrected. 1D 1H
and 13C NMR spectra were recorded on a Bruker 500 MHz
spectrometer using CDCl3 or DMSO-d6 as solvents. All chemical
shifts are reported in parts per million (ppm) and are relative to
internal (CH3)4Si (0 ppm) for
1H and CDCl3 (77.2 ppm) or DMSO-
d6 (39.5 ppm) for
13C NMR. EI GC-MS data were obtained using an
Agilent quadrapole mass spectrometer with 30 m DB-XLB type
columns and a He ﬂow rate of 1 mL/min. Silica gel (sg) particle size
32−63 μm was used for all ﬂash column chromatography. Reported
reaction temperatures are those of the oil bath. A Biotage microwave
reactor was used for selected reactions. Combustion analysis
conﬁrmed that all target compounds have a purity of at least 95%.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-1,5,5-trimethylimidazoli-
dine-2,4-dione (2). To a solution of 1 (700 mg, 2.4 mmol) in DMF
was added NaH (87 mg, 3.6 mmol) under Ar. The mixture was stirred
at rt for 30 min, and then iodomethane (514 mg, 3.6 mmol) was added
dropwise. After stirring for 2 h, the mixture was evaporated in vacuo to
give a residue which was extracted with brine (30 mL) and EtOAc (3
× 30 mL). The combined organic phase was washed with brine (2 ×
30 mL) and dried over MgSO4. After removal of the solvents, the
residue was puriﬁed by chromatography (sg, hexane:EtOAc, 4:1) to
aﬀord 2 as a white solid (580 mg, 79%). mp 110−112 °C; 1H NMR
Table 5. Exposure Parameters for Selected Aryl Hydantoins
in Male Swiss Outbred Mice Following Oral Administration
of 100 mg/kga
Compd Cmax (μM) Tmax (h) AUC0‑last (μM·h)
1 124 c.n.d. 2740
2 c.n.d. 1 c.n.d.
3 11.1 1 103
13 488 1 1360
14 112 3 3190
16 155 7 6480
23 26.6 1 163
26 15.0 1 106
ac.n.d. = could not determine.
Figure 3. Plasma concentration versus time proﬁles of (A) 16 (ﬁlled triangles) and 14 (open circles) and (B) 13 (ﬁlled squares), 23 (open circles),
and 26 (ﬁlled triangles), following oral administration of 100 mg/kg to male Swiss outbred mice. Symbols represent individual data points, and the
lines represent the mean proﬁles.
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(CDCl3) δ 1.51 (s, 6H), 2.98 (s, 3H), 7.29 (t, J = 9.3 Hz, 1H), 7.66−
7.69 (m, 1H), 7.77 (d, J = 6.3 Hz, 1H); 13C NMR (CDCl3) δ 22.28,
24.68, 61.22, 117.48 (m), 118.96 (qd, J = 33.6, 13.9 Hz), 122.03 (q, J =
272.5 Hz), 124.80 (m), 128.07 (d, J = 3.6 Hz), 131.23 (d, J = 8.6 Hz),
153.44, 158.48 (q, J = 258.2 Hz), 175.14. Anal. Calcd for
C13H12F4N2O2: C, 51.32; H, 3.98; N, 9.21; Found: C, 51.20; H,
3.92; N, 9.39.
1-Ethyl-3-[4-ﬂuoro-3-(triﬂuoromethyl)phenyl]-5,5-dimethylimi-
dazolidine-2,4-dione (3). To a solution of 1 (700 mg, 2.4 mmol) in
THF (7.5 mL) was added NaH (87 mg, 3.6 mmol) in THF (7.5 mL)
at 0 °C under Ar. The reaction mixture was then stirred at rt for 3 h
before dropwise addition of iodoethane (561 mg, 3.6 mmol). The
reaction mixture was stirred at rt for 72 h before quenching with acetic
acid (600 mg, 10 mmol) and H2O (1 mL). Solvent removal in vacuo
gave a residue which was crystallized from H2O. The residue was
further puriﬁed by chromatography (sg, EtOAc:hexane, 1:4) to aﬀord
3 as a white solid (301 mg, 39%). mp 90−91 °C; 1H NMR (CDCl3) δ
1.32 (t, J = 7.2 Hz, 3H), 1.53 (s, 6H), 3.43 (q, J = 7.2 Hz, 2H), 7.29 (t,
J = 9.4 Hz, 1H), 7.65−7.74 (m, 1H), 7.78 (dd, J = 6.3, 2.6 Hz, 1H).
13C NMR (CDCl3) δ 15.14, 23.58, 35.08, 61.97, 117.60 (d, J = 22.1
Hz), 119.11 (qd, J = 33.6, 13.6 Hz), 122.21 (q, J = 272.5 Hz), 124.95
(q, J = 4.5 Hz), 128.25 (d, J = 3.6 Hz), 131.34 (d, J = 8.9 Hz), 153.46,
158.60 (d, J = 258.1 Hz), 175.28. Anal. Calcd for C14H14F4N2O2: C,
52.83; H, 4.43; N, 8.80. Found: C, 52.80, H, 4.60, N, 8.71.
2-[3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5,5-dimethyl-2,4-diox-
oimidazolidin-1-yl]acetamide (4). To a solution of 1 (1.04 g, 3.6
mmol) in THF (15 mL) was added NaH (163 mg, 6.8 mmol) in THF
(15 mL) at 0 °C under Ar. The mixture was then stirred at rt for 3 h
before dropwise addition of 2-bromoacetamide (937 mg, 6.8 mmol).
The reaction mixture was stirred at rt for 72 h before quenching with
acetic acid (600 mg, 10 mmol). Solvent removal in vacuo gave a
residue which was crystallized from CH2Cl2 to aﬀord 4 as a white solid
(600 mg, 48%). mp 186−187 °C; 1H NMR (DMSO-d6) δ 1.43 (s,
6H), 3.90 (s, 2H), 7.25 (s, 1H), 7.50 (s, 1H), 7.69 (t, J = 9.7 Hz, 1H),
7.80−7.86 (m, 1H), 7.90 (dd, J = 6.6, 2.5 Hz, 1H); 13C NMR
(DMSO-d6) δ 22.04, 41.90, 61.62, 116.72 (qd, J = 32.9, 13.6 Hz),
117.84 (d, J = 21.8 Hz), 122.21 (q, J = 272.4 Hz), 125.36 (q, J = 5.0
Hz), 128.74 (d, J = 3.3 Hz), 133.37 (d, J = 9.3 Hz), 153.50, 157.56
(dq, J = 254.9, 1.9 Hz), 169.63, 175.02. Anal. Calcd for C14H13F4N3O3:
C, 48.42; H, 3.77; N, 12.10. Found: C, 48.70, H, 4.01, N, 11.89.
2-[3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5,5-dimethyl-2,4-diox-
oimidazolidin-1-yl]acetonitrile (5). To a solution of 1 (700 mg, 2.4
mmol) in DMF was added NaH (116 mg, 4.8 mmol) under Ar. The
mixture was stirred at rt for 30 min, and then 2-bromoacetonitrile (578
mg, 4.8 mmol) was added dropwise. After stirring for 2 h, the mixture
was evaporated in vacuo to give a residue which was extracted with
brine (30 mL) and EtOAc (3 × 30 mL). The combined organic phase
was washed with brine (2 × 30 mL) and dried over MgSO4. After
removal of the solvents, the residue was puriﬁed by chromatography
(sg, hexane:EtOAc, 2:1) to aﬀord 5 as a white solid (573 mg, 72%).
mp 147−149 °C; 1H NMR (CDCl3) δ 1.65 (s, 6H), 4.37 (s, 2H), 7.32
(t, J = 9.3 Hz, 1H), 7.66−7.69 (m, 1H), 7.75 (dd, J = 2.4, 5.9 Hz, 1H);
13C NMR (CDCl3) δ 22.75, 27.14, 62.11, 114.73, 117.81 (d, J = 22.1
Hz), 119.28 (qd, J = 33.6, 13.9 Hz), 121.90 (q, J = 273.0 Hz), 124.89
(q, J = 1.9 Hz), 127.28(d, J = 4.4 Hz), 131.27 (d, J = 9.6 Hz), 153.13,
158.83(q, J = 257.2 Hz), 173.71. Anal. Calcd for C14H11F4N3O2: C,
51.07; H, 3.37; N, 12.76; Found: C, 51.29; H, 3.60; N, 12.52.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5,5-dimethyl-1-phenethy-
limidazolidine-2,4-dione (6). To a solution of 1 (700 mg, 2.4 mmol)
in DMF (15 mL) was added NaH (87 mg, 3.6 mmol) under Ar. The
mixture was stirred at rt for 30 min, and then 2-bromoethylbenzene
(670 mg, 3.6 mmol) was added dropwise. After stirring for 2 h, the
mixture was evaporated in vacuo to give a residue which was extracted
with brine (30 mL) and EtOAc (3 × 30 mL). The combined organic
phase was washed with brine (2 × 30 mL) and dried over MgSO4.
After removal of the solvents, the residue was puriﬁed by
chromatography (sg, hexane:EtOAc, 4:1) to aﬀord 6 as a white solid
(410 mg, 43%). mp 98−100 °C; 1H NMR (CDCl3) δ 1.39 (s, 6H),
3.05 (t, J = 7.8 Hz, 2H), 3.53 (t, J = 8.3 Hz, 2H), 7.24−7.34 (m, 6H),
7.69−7.72 (m, 1H), 7.78 (dd, J = 2.4, 6.9 Hz, 1H); 13C NMR (CDCl3)
δ 23.12, 35.34, 42.23, 61.86, 117.46 (d, J = 22.2 Hz), 118.94 (qd, J =
33.1, 13.9 Hz), 122.04 (q, J = 272.0 Hz), 124.72 (m), 126.81, 128.69,
128.81, 131.14 (d, J = 8.5 Hz), 138.23, 153.62, 158.49 (d, J = 258.2
Hz), 174.94. Anal. Calcd for C20H18F4N2O2: C, 60.91; H, 4.60; N,
7.10; Found: C, 60.70; H, 4.89; N, 7.26.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5,5-dimethyl-1-
(methylsulfonyl)imidazolidine-2,4-dione (7). To a solution of 1 (700
mg, 2.4 mmol) in THF (7.5 mL) was added NaH (100 mg, 4.1 mmol)
in THF (7.5 mL) at 0 °C under Ar. The reaction mixture was then
stirred at rt for 30 min before dropwise addition of methanesulfonyl
chloride (410 mg, 3.6 mmol). After further stirring at rt for 72 h, the
reaction was quenched with acetic acid (4 mL). Removal of solvents in
vacuo gave a residue to which was added H2O (30 mL). The resulting
precipitate was ﬁltered and crystallized from 1:5 EtOAc:hexane to
aﬀord 7 as a white solid (812 mg, 92%). mp 207−208 °C; 1H NMR
(CDCl3) δ 1.86 (s, 6H), 3.44 (s, 3H), 7.35 (t, J = 9.2 Hz, 1H), 7.67
(dt, J = 7.4, 3.5 Hz, 1H), 7.75 (dd, J = 6.1, 2.7 Hz, 1H). 13C NMR
(CDCl3) δ 24.19, 43.53, 66.73, 118.19 (d, J = 22.3 Hz), 119.70 (qd, J =
33.9, 13.9 Hz), 121.95 (q, J = 272.6 Hz), 125.36 (qd, J = 6.9, 4.5 Hz),
126.56, 131.70 (d, J = 9.4 Hz), 151.70, 159.31 (d, J = 259.9 Hz),
173.02. Anal. Calcd for C13H12F4N2O4S: C, 42.39; H, 3.28; N, 7.61.
Found: C, 42.40; H, 3.46; N, 7.49.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5,5-dimethyl-1-
(phenylsulfonyl)imidazolidine-2,4-dione (8). To a solution of 1 (700
mg, 2.4 mmol) in DMF (15 mL) was added NaH (87 mg, 3.6 mmol)
under Ar. The mixture was stirred at rt for 30 min, and then
benzenesulfonyl chloride (639 mg, 3.6 mmol) was added dropwise.
After stirring for 2 h, the mixture was evaporated in vacuo to give a
residue which was extracted with brine (30 mL) and EtOAc (3 × 30
mL). The combined organic phase was washed with brine (2 × 30
mL) and dried over MgSO4. After removal of the solvents, the residue
was puriﬁed by chromatography (sg, hexane:EtOAc, 4:1) to aﬀord 8 as
a white solid (739 mg, 71%). mp 153−155 °C; 1H NMR (CDCl3) δ
1.92 (s, 6H), 7.27 (t, J = 9.4 Hz, 1H), 7.57−7.71 (m, 5H), 8.13 (d, J =
8.3 Hz, 2H); 13C NMR (CDCl3) δ 24.26, 66.75, 117.80 (d, J = 22.2
Hz), 119.29 (qd, J = 34.1, 13.9 Hz), 121.77(q, J = 272.5 Hz), 125.14
(m), 126.46 (d, J = 3.8 Hz), 128.73, 129.16, 131.54 (d, J = 9.1 Hz),
134.59, 138.32, 150.57, 158.99 (d, J = 259.6 Hz), 172.81. Anal. Calcd
for C18H14F4N2O4S 0.67 H2O: C, 48.87; H, 3.49; N, 6.33; Found: C,
48.71; H, 3.09; N, 6.12.
5,5-Dimethyl -3- [4-methyl -3- ( t r iﬂuoromethyl )phenyl ]-
imidazolidine-2,4-dione (11). To a solution of 5,5-dimethylimidazo-
lidine-2,4-dione (42) (568 mg, 4.44 mmol) and Cu2O (240 mg, 1.68
mmol) in DMA (15 mL) was added 4-iodo-1-methyl-2-
(triﬂuoromethyl)benzene (37) (1.00 g, 3.5 mmol). After stirring at
160 °C for 12 h, the solvent was evaporated in vacuo to give a crude
product which was further puriﬁed by sg chromatography using
successive elution with hexane, EtOAc, and EtOH to aﬀord 11 as a
white solid (536 mg, 54%). mp 134−135 °C; 1H NMR (CDCl3) δ
1.57 (s, 6H), 2.51 (s, 3H), 5.52 (s, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.50
(d, J = 7.9 Hz, 1H), 7.70 (s, 1H); 13C NMR (DMSO-d6) δ 18.43,
24.65, 57.85, 123.92 (q, J = 5.2 Hz), 124.09 (q, J = 273.6 Hz), 127.54
(q, J = 29.6 Hz), 130.37, 130.41, 132.59, 135.53, 153.85, 176.21. Anal.
Calcd for C13H13F3N2O2: C, 54.55; H, 4.58; N, 9.79; Found: C, 54.45;
H, 4.73; N, 9.62.
5-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-2-ﬂuorobenzonitrile
(12). To a solution of 42 (0.674, 5.3 mmol) and Cu2O (290 mg, 2
mmol) in DMA (4 mL) was added 2-ﬂuoro-5-iodobenzonitrile (38)
(1.0 g, 4.1 mmol). After it was heated to 160 °C for 48 h, the solvent
was evaporated in vacuo. After addition of EtOAc (100 mL), the
resulting precipitate was ﬁltered and the ﬁltrate was concentrated and
puriﬁed by chromatography (sg, EtOAc) followed by recrystallization
from 1:20 ethanol:H2O to aﬀord 12 as a white solid (768 mg, 77%).
mp 145−147 °C; 1H NMR (CDCl3) δ 1.56 (s, 6H), 6.70 (s, 1H), 7.33
(t, J = 8.8 Hz, 1H), 7.78−7.81 (m, 1H), 7.84 (dd, J = 2.4, 5.4 Hz, 1H);
13C NMR (DMSO-d6) δ 25.15, 58.83, 102.08(d, J = 17.3 Hz), 112.99,
117.08 (d, J = 21.1 Hz), 128.52 (d, J = 3.4 Hz), 130.48, 132.28 (d, J =
8.6 Hz), 154.41, 161.74 (d, J = 261.0 Hz),175.47. Anal. Calcd for
C12H10FN3O2: C, 58.30; H, 4.08; N, 17.00; Found: C, 58.08; H, 4.26;
N, 17.28.
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5-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-2-ﬂuoro-N,N-dime-
thylbenzamide (13). To a solution of 42 (640 mg, 5.0 mmol) and
Cu2O (259 mg, 1.8 mmol) in DMA (10 mL) was added 2-ﬂuoro-5-
iodo-N,N-dimethylbenzamide (39) (496 mg, 1.7 mmol). The mixture
was then heated to 150 °C for 48 h. Solvent removal in vacuo gave a
crude product which was further puriﬁed by sg chromatography using
successive elution with hexane, EtOAc, and ethanol followed by
crystallization from a 1:10 EtOAc:hexane mixture to aﬀord 13 as a
white solid (296 mg, 58%). mp 166−168 °C; 1H NMR (DMSO-d6) δ
1.40 (s, 6H), 2.87 (s, 3H), 3.01 (s, 3H), 7.41 (t, J = 9.1 Hz, 1H), 7.44
(dd, J = 6.0, 2.5 Hz, 1H), 7.51 (ddd, J = 8.9, 4.8, 2.6 Hz, 1H), 8.59 (s,
1H). 13C NMR (DMSO-d6) δ 24.68, 34.33, 37.85, 57.85, 116.21 (d, J
= 23.3 Hz), 124.76 (d, J = 20.0 Hz), 127.11 (d, J = 4.7 Hz), 128.69 (d,
J = 3.0 Hz), 129.62 (d, J = 8.7 Hz), 153.93, 156.32 (d, J = 246.5 Hz),
164.45, 176.27. Anal. Calcd for C14H16FN3O3: C, 57.33; H, 5.50; N,
14.33. Found: C, 57.51; H, 5.25; N, 14.22.
3-[3-(Diﬂuoromethyl)-4-ﬂuorophenyl]-5,5-dimethylimidazoli-
dine-2,4-dione (14). To a solution of 42 (2.54 g, 19.8 mmol) and
Cu2O (1.09 g, 7.6 mmol) in DMA (30 mL) was added 4-bromo-2-
(diﬂuoromethyl)-1-ﬂuorobenzene (49) (3.50 g, 15.5 mmol). After the
reaction mixture was heated at 160 °C for 24 h, the solvent was
removed in vacuo. The residue was puriﬁed by chromatography (sg,
EtOAc) and then crystallized successively from hexane (15 mL) and
H2O (20 mL) to aﬀord 14 as a white solid (3.43 g, 81%). mp 158−159
°C; 1H NMR (DMSO-d6) δ 1.41 (s, 6H), 7.26 (t, J = 54.1 Hz, 1H),
7.51 (t, J = 9.5 Hz, 1H), 7.59−7.68 (m, 1H), 7.72 (dd, J = 6.4, 2.5 Hz,
1H), 8.62 (s, 1H). 13C NMR (DMSO-d6) δ 24.60, 57.85, 111.52 (td, J
= 236.2, 3.5 Hz), 116.72 (d, J = 21.8 Hz), 121.46 (td, J = 23.4, 14.0
Hz), 125.75 (d, J = 3.3 Hz), 128.68 (d, J = 3.3 Hz), 131.64 (d, J = 9.0
Hz), 153.79, 158.38 (dt, J = 251.3, 4.8 Hz), 176.17. Anal. Calcd for
C12H11F3N2O2: C, 52.94; H, 4.07; N, 10.29. Found: C, 52.72, H, 4.19,
N, 10.12.
5,5-Dimethyl-3-(pyridin-4-yl)imidazolidine-2,4-dione (15). To a
solution of 42 (5.38 g, 42 mmol) and Cu(OAc)2 (543 mg, 3 mmol) in
methanol (150 mL) was added pyridin-4-ylboronic acid (53) (3.6 g,
29 mmol) under O2. The mixture was heated at 70 °C overnight. The
solvent was then ﬁltered through silica gel to remove copper, and the
resulting cake was washed with methanol (100 mL). Evaporation of
the ﬁltrate gave a crude product which was further puriﬁed by
crystallization from a saturated Na2CO3 solution (20 mL) to aﬀord 15
as a white solid (2.8 g, 47%). mp 201−203 °C; 1H NMR (DMSO-d6)
δ 1.42 (s, 6H), 7.57 (d, J = 5.6 Hz, 2H), 8.67 (d, J = 6.1 Hz, 2H), 8.74
(brs, 1H). 13C NMR (DMSO-d6) δ 24.70, 57.75, 119.62, 139.85,
150.26, 153.08, 175.88. Anal. Calcd for C10H11N3O2: C, 58.53; H,
5.40; N, 20.48. Found: C, 58.14; H, 5.64; N, 20.57.
5,5-Dimethyl-3-[2-(triﬂuoromethyl)pyridin-4-yl]imidazolidine-
2,4-dione (16). To a solution of 42 (776 mg, 6.1 mmol) and Cu2O
(288 mg, 2.0 mmol) in DMA (30 mL) was added 4-iodo-2-
(triﬂuoromethyl)pyridine (39) (750 mg, 2.8 mmol). After stirring at
140 °C for 24 h, the solvent was evaporated in vacuo to give a crude
product which was further puriﬁed by sg chromatography using
successive elution with hexane and EtOAc to aﬀord 16 as a white solid
(674 mg, 90%). mp 195−197 °C; 1H NMR (DMSO-d6) δ 1.43 (s,
6H), 7.95 (dd, J = 5.4, 1.9 Hz, 1H), 8.14 (d, J = 1.8, 1H), 8.87 (d, J =
5.4 Hz, 1H), 8.89 (br s, 1H); 13C NMR (DMSO-d6) δ 24.61, 57.82,
116.17, 121.39 (q, J = 274.3 Hz), 122.29, 141.72, 146.94 (q, J = 34.1
Hz), 151.15, 152.68, 175.71. Anal. Calcd for C11H10F3N3O2: C, 48.36;
H, 3.69; N, 15.38. Found: C, 47.97; H, 4.00; N, 15.64.
5,5-Dimethyl-3-(quinolin-4-yl)imidazolidine-2,4-dione (17). To a
solution of 42 (384 mg, 3 mmol) and Cu2O (142 mg, 1 mmol) in
DMA (5 mL) was added 4-iodoquinoline (44) (163 mg, 0.64 mmol).
After the reaction mixture was heated at 150 °C for 72 h, the solvent
was removed in vacuo. The residue was puriﬁed by sg chromatography
using successive elution with hexane, EtOAc, and ethanol to aﬀord 17
as a pale yellow solid (101 mg, 62%). mp 194−196 °C; 1H NMR
(DMSO-d6) δ 1.50 (s, 3H), 1.57 (s, 3H), 7.61 (d, J = 4.6 Hz, 1H),
7.65−7.76 (m, 2H), 7.86 (t, J = 7.2 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H),
8.83 (s, 1H), 9.05 (d, J = 4.6 Hz, 1H); 13C NMR (DMSO-d6) δ 24.50,
25.26, 58.77, 121.60, 122.83, 124.72, 127.58, 129.42, 130.15, 137.08,
148.77, 150.73, 153.60, 176.45. Anal. Calcd for C14H13N3O2 H2O: C,
61.53; H, 5.53; N, 15.38. Found: C, 61.82; H, 5.08; N, 15.30.
5,5-Dimethyl-3-(pyridin-3-yl)imidazolidine-2,4-dione (18). To a
solution of 42 (1.792 g, 14 mmol) and Cu(OAc)2 (181 mg, 1 mmol)
in methanol (50 mL) was added pyridin-3-ylboronic acid (52) (1.23 g,
10 mmol) under O2. The mixture was heated at 70 °C overnight. The
solvent was then ﬁltered through silica gel to remove copper, and the
resulting cake was washed with methanol (100 mL). Evaporation of
the ﬁltrate gave a crude product which was further puriﬁed by
successive crystallizations from diethyl ether (10 mL) and saturated
Na2CO3 (10 mL) to aﬀord 18 as a white solid (1.258 g, 61%). mp
160−162 °C; 1H NMR (CDCl3) δ 1.56 (s, 6H), 6.85 (s, 1H), 7.43
(dd, J = 4.4, 7.8 Hz, 1H), 7.84 (d, J = 8.3 Hz, 1H), 8.62 (d, J = 4.4 Hz,
1H), 8.78 (s, 1H); 13C NMR (CDCl3) δ 25.22, 58.87, 123.57, 128.78,
133.15, 146.79, 148.65, 154.72, 175.79. Anal. Calcd for C10H11N3O2:
C, 58.53; H, 5.40; N, 20.48; Found: C, 58.70; H, 5.36; N, 20.19.
5,5-Dimethyl-3-[6-(triﬂuoromethyl)pyridin-3-yl]imidazolidine-
2,4-dione (19). To a solution of 42 (384 mg, 3.00 mmol) and Cu2O
(143 mg, 1.00 mmol) in DMA (10 mL) was added 5-iodo-2-
(triﬂuoromethyl)pyridine (41) (476 mg, 1.74 mmol), and the mixture
was heated to 140 °C for 48 h. After solvent removal in vacuo, the
crude product was puriﬁed by sg chromatography using successive
elution with hexane and EtOAc. After removal of the solvents in vacuo,
the residue was crystallized from 1:20 EtOAc:hexane. The resulting
precipitate was collected by ﬁltration and rinsed by H2O (5 mL) to
give 19 as a white solid (357 mg, 75%). mp 173−174 °C; 1H NMR
(DMSO-d6) δ 1.44 (s, 6 H), 8.08 (d, J = 8.3 Hz, 1 H), 8.20 (d, J = 8.3
Hz, 1 H), 8.80 (s, 1 H), 8.88 (s, 1 H); 13C NMR (DMSO-d6) δ 24.80,
58.36, 121.16, 121.61(q, J = 273.9 Hz), 132.27, 135.50, 144.63 (q, J =
34.4 Hz), 147.43, 153.32,176.10. Anal. Calcd for C11H10F3N3O2: C,
48.36; H, 3.69; N, 15.38. Found C, 48.48; H, 3.81; N, 15.16.
5,5-Dimethyl-3-(pyrazin-2-yl)imidazolidine-2,4-dione (20). To a
solution of 42 (1.28 g, 10.0 mmol) and Cu2O (357.5 mg, 2.5 mmol) in
DMA (20 mL) was added 2-iodopyrazine (43) (1.00 g, 4.9 mmol).
The reaction mixture was then heated to 140 °C for 24 h. After solvent
removal in vacuo, the crude product was puriﬁed by sg
chromatography using successive elutions with hexane, EtOAc, and
ethanol. After removal of the solvents in vacuo, the residue was
crystallized from a mixture of ether (0.5 mL) and hexane (10 mL).
The resulting precipitate was collected by ﬁltration to give 20 as a pale
yellow solid (210 mg, 21%). mp 149−151 °C; 1H NMR (DMSO-d6) δ
1.44 (s, 6H), 8.66−8.90 (m, 4H); 13C NMR (DMSO-d6) δ 24.65,
58.38, 142.76, 143.72, 143.91, 144.38, 153.05, 175.80. Anal. Calcd for
C9H10N4O2; C, 52.42; H, 4.89; N, 27.17. Found: C, 52.34; H, 5.00; N,
27.21.
3-[4-Fluoro-3-(triﬂuoromethyl)benzyl]-5,5-dimethylimidazoli-
dine-2,4-dione (21). A mixture of 4-(bromomethyl)-1-ﬂuoro-2-
(triﬂuoromethyl)benzene (50) (1.552 g, 6.0 mmol), 42 (647 mg,
5.1 mmol), and K2CO3 (2.004 g, 14.5 mmol) in DMA (12.5 mL) was
stirred at 85 °C for 24 h. The mixture was extracted with EtOAc (3 ×
50 mL) and H2O (50 mL). The organic phase was combined, dried,
and evaporated in vacuo to give a residue which was further puriﬁed by
chromatography (sg, EtOAc:hexane, 1:3) and crystallized from H2O to
aﬀord 21 as a white solid (1.16 g, 75%). mp 86−87 °C; 1H NMR
(DMSO-d6) δ 1.32 (s, 6H), 4.63 (s, 2H), 7.50 (dd, J = 10.7, 8.6 Hz,
1H), 7.56−7.63 (m, 1H), 7.66 (d, J = 7.0 Hz, 1H), 8.46 (s, 1H); 13C
NMR (DMSO-d6) δ 24.53, 39.91, 58.03, 116.53 (qd, J = 32.4, 12.6
Hz), 117.55 (d, J = 20.7 Hz), 122.47 (q, J = 272.0 Hz), 126.07 (q, J =
4.7 Hz), 133.99, 134.04 (d, J = 5.3 Hz), 154.91, 158.10 (dq, J = 253.2,
2.3 Hz), 177.22. Anal. Calcd for C13H12F4N2O2: C, 51.32; H, 3.98; N,
9.21. Found: C, 51.49; H, 4.12; N, 9.34.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5-methylimidazolidine-
2,4-dione (23). Step 1. To a solution of 2-aminopropanoic acid (57)
(2.225 g, 25 mmol) in 1 M NaOH (40 mL) was added 1-ﬂuoro-4-
isocyanato-2-(triﬂuoromethyl)benzene (56) (6.15 g, 30 mmol) in
CH3CN (15 mL) at 0 °C dropwise. The reaction mixture was stirred
at 0 °C for 3 h and then warmed to rt overnight. Step 2. The reaction
mixture was adjusted to pH 3.0 by 32% HCl and concentrated in
vacuo. The resulting precipitate was crystallized from 1:40
EtOAc:hexane to give 2-[3-[4-ﬂuoro-3-(triﬂuoromethyl)phenyl]-
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ureido]propanoic acid as a white solid (5.157 g, 70%), 1.1 g (3.74
mmol) of which was suspended in 4 M HCl (50 mL) and then heated
at 110 °C overnight. After the reaction mixture was cooled to rt, the
resulting precipitate was ﬁltered to aﬀord 23 as a white solid (845 mg,
82%). mp 153−154 °C; 1H NMR (DMSO-d6) δ 1.38 (d, J = 6.9 Hz,
3H), 4.27 (q, J = 6.9 Hz, 1H), 7.65 (t, J = 9.7 Hz, 1H), 7.76−7.83 (m,
1H), 7.87 (dd, J = 6.7, 2.5 Hz, 1H), 8.59 (s, 1H); 13C NMR (DMSO-
d6) δ 16.94, 52.23, 116.73 (qd, J = 32.8, 13.4 Hz), 117.76 (d, J = 21.8
Hz), 122.23 (q, J = 272.1 Hz), 125.47 (q, J = 5.1 Hz), 128.95 (d, J =
3.5 Hz), 133.43 (d, J = 9.3 Hz), 154.84, 157.50 (dq, J = 254.3, 2.1 Hz),
173.81. Anal. Calcd for C11H8F4N2O2·0.5H2O: C, 46.33; H, 3.18; N,
9.82; Found: C, 46.61; H, 3.19; N, 9.81.
(R)-3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5-phenylimidazoli-
dine-2,4-dione (24). Step 1. To a solution of (R)-2-amino-2-
phenylacetic acid (58) (1.057 g, 7.0 mmol) in 1 M NaOH (10 mL)
was added 56 (2.05 g, 10 mmol) in CH3CN (5 mL) at 0 °C dropwise.
The mixture was stirred at 0 °C for 3 h, and then 1,4-dioxane (10 mL)
was added according to the method of Cooper et al.44 After stirring at
rt for 12 h, the reaction mixture was adjusted to pH 2 by 32% HCl and
concentrated in vacuo. Step 2. The resulting precipitate was
successively crystallized from 1:10 EtOH:H2O and 1:10 EtOAc:hexane
to give (R)-2-[3-[4-ﬂuoro-3-(triﬂuoromethyl)phenyl]ureido]-2-phe-
nylacetic acid as a white solid (1.661 g, 67%), 818 mg of which was
then suspended in 4 M HCl (50 mL) and heated at 110 °C overnight.
After the reaction mixture was cooled to 0 °C, the resulting precipitate
was ﬁltered to give 24 as a white solid (678 mg, 87%). mp 166−168
°C; 1H NMR (DMSO-d6) δ 5.37 (s, 1H), 7.33−7.54 (m, 5H), 7.67
(dd, J = 10.0, 9.7 Hz, 1H), 7.78−7.88 (m, 1H), 7.92 (dd, J = 6.7, 2.5
Hz, 1H), 9.10 (s, 1H). 13C NMR (DMSO-d6) δ 60.36, 117.01 (qd, J =
32.8, 13.5 Hz), 118.05 (d, J = 21.8 Hz), 122.40 (q, J = 272.7 Hz),
125.89, 127.55, 128.76, 128.89, 128.97 (d, J = 3.4 Hz), 133.80 (d, J =
9.3 Hz), 135.55, 155.33, 157.85 (d, J = 258.6 Hz), 171.60. Anal. Calcd
for C16H10F4N2O2: C, 56.81; H, 2.98; N, 8.28. Found: C, 56.66; H,
3.12; N, 8.18.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5-(hydroxymethyl)-5-
methylimidazolidine-2,4-dione (25). Step 1. To a solution of 2-
amino-3-hydroxy-2-methylpropanoic acid (59) (537 mg, 4.5 mmol) in
dioxane (23 mL) was added 56 (8.10 g, 39.5 mmol) under Ar. After
the reaction mixture was stirred at 80 °C for 6 h, it was cooled to rt,
diluted with CH2Cl2 (25 mL), and extracted with 2 M NaOH (3 × 25
mL). After the combined aqueous layers were separated and ﬁltered to
remove the insoluble N,N-diarylurea side product, the ﬁltrate was
acidiﬁed with 2 M HCl (100 mL) and concentrated. Step 2. The
residue was suspended in 2 M HCl (50 mL) and then heated at 110
°C for 4 h. After the reaction mixture was cooled to rt, the resulting
precipitate was collected by ﬁltration to give 25 (370 mg, 27%) as a
white solid. mp 166−168 °C; 1H NMR (DMSO-d6) δ 1.30 (s, 3H),
3.43 (d, J = 10.7 Hz, 1H), 3.67 (d, J = 11.2 Hz, 1H), 7.66 (t, J = 10.3
Hz, 1H), 7.76−7.77 (m, 1H), 7.81 (d, J = 6.3, 1H), 8.52 (s, 1H); 13C
NMR (DMSO-d6) 18.97, 63.52, 65.38, 117.00 (q, J = 32.5 Hz), 118.07
(d, J = 22.0 Hz), 122.40 (q, J = 273.0 Hz), 125.20, 129.15, 133.29 (d, J
= 9.2 Hz), 154.78, 157.61 (d, J = 254.2 Hz), 175.04. Anal. Calcd for
C12H10F4N2O3: C, 47.07; H, 3.29; N, 9.15. Found: C, 46.91, H, 3.46,
N, 9.32.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-1,3-diazaspiro[4.4]-
nonane-2,4-dione (26). Step 1. To a solution of 1-amino-
cyclopentane-1-carboxylic acid (60) (1.161 g, 9.0 mmol) in 1 M
NaOH (15 mL) was added a solution of 56 (1.83 g, 8.9 mmol) in
CH3CN (10 mL) at 0 °C dropwise. The mixture was stirred at 0 °C
for 3 h and then warmed to rt overnight. The reaction mixture was
adjusted to pH 1.0 by 32% HCl and concentrated in vacuo. Step 2.
The resulting precipitate was collected by ﬁltration, and the solid was
then suspended in 4 M HCl (50 mL) and heated at 110 °C overnight.
After the reaction mixture was cooled to rt, the resulting precipitate
was ﬁltered and crystallized from diethyl ether to give 26 as a white
solid (660 mg, 23%). mp 151−152 °C; 1H NMR (DMSO-d6) δ 1.67−
1.92 (m, 6H), 2.01−2.16 (m, 2H), 7.65 (dd, J = 10.5, 9.0 Hz, 1H),
7.78−7.84 (m, 1H), 7.90 (dd, J = 6.6, 2.6 Hz, 1H), 8.86 (s, 1H); 13C
NMR (DMSO-d6) δ 24.82, 37.58, 67.49, 116.86 (qd, J = 33.2, 13.4
Hz), 117.89 (d, J = 21.9 Hz), 122.43 (q, J = 272.4 Hz), 125.72, 129.14,
133.61 (d, J = 9.0 Hz), 154.16, 157.65 (d, J = 253.1 Hz), 176.55. Anal.
Calcd for C14H12F4N2O2: C, 53.17; H, 3.82; N, 8.86. Found: C, 52.89;
H, 4.00; N, 8.89.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-1,3-diazaspiro[4.5]-
decane-2,4-dione (27). To a solution of 1,3-diazaspiro[4.5]decane-
2,4-dione (46) (840 mg, 5.0 mmol) and Cu2O (290 mg, 2.0 mmol) in
DMA (20 mL) was added 1-ﬂuoro-4-iodo-2-(triﬂuoromethyl)benzene
(45) (1170 mg, 4.0 mmol). After it was heated at 160 °C for 24 h, the
solvent was evaporated in vacuo. The residue was puriﬁed by sg
chromatography (EtOAc) to aﬀord 27 as a white solid (917 mg, 69%).
mp 213-215 °C; 1H NMR (DMSO-d6) δ 1.25−1.40 (m, 1H) 1.58 (br
s, 3H) 1.64−1.83 (m, 6H) 7.65 (t, J = 9.7 Hz, 1H), 7.77−7.84 (m,
1H) 7.89 (d, J = 6.35 Hz, 1H) 9.05 (br s, 1H); 13C NMR (DMSO-d6)
δ 20.93, 24.56, 33.33, 61.27, 116.88 (qd, J = 33.0, 13.3), 117.9 (d, J =
22.0), 122.4 (q, J = 272.5), 125.87 (d, J = 4.1), 129.03, 133.76 (d, J =
9.2), 154.27, 157.7 (d, J = 254.7), 175.64. Anal. Calcd for
C15H14F4N2O2: C, 54.55; H, 4.27; N, 8.48. Found: C, 54.38; H,
4.40; N, 8.49.
2-[4-Fluoro-3-(triﬂuoromethyl)phenyl]tetrahydro-1H-pyrrolo[1,2-
c]imidazole-1,3(2H)-dione (28). To a solution of tetrahydro-1H-
pyrrolo[1,2-c]imidazole-1,3(2H)-dione (55) (538 mg, 3.8 mmol),
Cu(OAc)2 (1.370 g, 7.6 mmol), and pyridine (900 mg, 11.4 mmol) in
CH2Cl2 (38 mL) was added [4-ﬂuoro-3-(triﬂuoromethyl)phenyl]-
boronic acid (53) (2.359 g, 11.3 mmol). After stirring at rt for 7 days,
the solvent was removed in vacuo. The residue was puriﬁed by
chromatography (sg, EtOAc) and then crystallized from hexane to
aﬀord 28 as a white solid (443 mg, 39%). mp 146−148 °C; 1H NMR
(CDCl3) δ 1.78−1.93 (m, 1H), 2.06−2.30 (m, 2H), 2.32−2.45 (m,
1H), 3.37 (ddd, J = 11.6, 8.5, 4.6 Hz, 1H), 3.80 (dt, J = 11.5, 7.8 Hz,
1H), 4.27 (dd, J = 9.4, 7.5 Hz, 1H), 7.29 (t, J = 9.3 Hz, 1H), 7.60−7.68
(m, 1H), 7.74 (dd, J = 6.2, 2.6 Hz, 1H); 13C NMR (DMSO-d6) δ
26.38, 26.50, 45.30, 62.94, 116.77 (qd, J = 33.1, 13.5 Hz), 117.87 (d, J
= 21.8 Hz), 122.20 (q, J = 272.0 Hz), 125.68, 128.89 (d, J = 3.4 Hz),
133.59 (d, J = 9.4 Hz), 157.66 (d, J = 255.0 Hz), 158.26, 172.45. Anal.
Calcd for C13H10F4N2O2: C, 51.66; H, 3.34; N, 9.27. Found: C, 51.70;
H, 3.40; N, 9.55.
1-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-3,3-dimethylpyrrolidine-
2,5-dione (29). To a solution of 3,3-dimethylpyrrolidine-2,5-dione
(47) (1.71 g, 13.5 mmol) and Cu2O (0.74 g, 5.2 mmol) in DMF (15
mL) was added 1-ﬂuoro-4-iodo-2-(triﬂuoromethyl)benzene (45) (3.0
g, 10.3 mmol), and the mixture was heated to reﬂux for 48 h. After
cooling to rt, the solvent was evaporated in vacuo. After addition of
concentrated NH4OH (20 mL) and H2O (15 mL), the resulting
precipitate was ﬁltered and puriﬁed by chromatography (sg,
hexane:EtOAc, 5:1) to aﬀord 29 as a white solid (1.39 g, 46%). mp
134−136 °C; 1H NMR (CDCl3) δ 1.44 (s, 6H), 2.74 (s, 2H), 7.33 (t, J
= 9.3 Hz, 1H), 7.53−7.56 (m, 1H), 7.62 (d, J = 5.9 Hz, 1H);13C NMR
(CDCl3) δ 25.60, 40.23, 43.62, 117.67 (d, J = 22.1 Hz), 119.15 (qd, J =
34.6, 13.4 Hz), 121.95(q, J = 272.5 Hz), 125.33 (m), 128.0 (d, J = 3.8
Hz), 131.9(d, J = 8.6 Hz), 158.89 (d, J = 258.6 Hz), 174.20, 181.67.
Anal. Calcd for C13H11F4NO2: C, 53.99; H, 3.83; N, 4.84; Found: C,
54.00; H, 3.82; N, 4.89.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5,5-dimethyloxazolidine-
2,4-dione (30). To a solution of 5,5-dimethyloxazolidine-2,4-dione
(54) (903 mg, 7.0 mmol) and Cu(OAc)2 (90 mg, 0.5 mmol) in
methanol (25 mL) was added (4-ﬂuoro-3-(triﬂuoromethyl)phenyl)-
boronic acid (53) (1.04 g, 5.0 mmol) under O2. The mixture was
heated at 70 °C overnight. After cooling to rt, the solvent was
evaporated in vacuo. The residue was puriﬁed by chromatography with
successive elution with hexane and EtOAc followed by crystallization
from 1:10 ethanol:H2O to aﬀord 30 as a white solid (421 mg, 29%).
mp 174−176 °C; 1H NMR (CDCl3) δ 1.70 (s, 6H), 7.34 (t, J = 8.8
Hz, 1H), 7.69−7.72 (m, 1H), 7.79 (dd, J = 2.4, 5.9 Hz, 1H); 13C NMR
(CDCl3) δ 23.74, 83.80, 117.99 (d, J = 22.1 Hz), 119.48 (qd, J = 34.1,
20.2 Hz), 121.81 (q, J = 272.5 Hz), 124.53 (m), 127.12 (d, J = 3.4
Hz), 130.89 (d, J = 9.1 Hz), 152.54, 159.01 (dq, J = 259.6, 1.9 Hz),
174.32. Anal. Calcd for C12H9F4NO3: C, 49.49; H, 3.12; N, 4.81;
Found: C, 49.21; H, 3.06; N, 4.80.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5,5-dimethylpyrrolidine-
2,4-dione (31). Step 1. A mixture of 2-[4-ﬂuoro-3-(triﬂuoromethyl)-
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phenyl]acetic acid (2.22 g, 10 mmol) and SOCl2 (4 mL) was stirred at
80 °C overnight. The reaction mixture was concentrated in vacuo to
aﬀord 2-[4-ﬂuoro-3-(triﬂuoromethyl)phenyl]acetyl chloride (65),
which was used for the next step without further puriﬁcation. Step
2. To a solution of methyl 2-amino-2-methylpropanoate HCl salt
(1.53 g, 10 mmol) and Et3N (5.0 g, 50 mmol) in THF (47.5 mL) was
added 65 in THF (2.5 mL), and the reaction mixture was stirred at rt
overnight. After ﬁltration to remove insoluble TEA HCl salt, the
ﬁltrate was concentrated in vacuo. The residue was puriﬁed by
chromatography (sg, EtOAc:hexane, 1:1) to aﬀord methyl 2-[2-[4-
ﬂuoro-3-(triﬂuoromethyl)phenyl]acetamido]-2-methylpropanoate
(66) as a white solid (1.13 g, 35%). 1H NMR (DMSO-d6) δ 1.35 (s,
6H), 3.50 (s, 3H), 3.52 (s, 2H), 7.45 (dd, J = 10.9, 8.6 Hz, 1H), 7.52−
7.61 (m, 1H), 7.63 (d, J = 7.7 Hz, 1H), 8.54 (s, 1H). Step 3. To a
solution of 66 (860 mg, 2.68 mmol) in THF (7 mL) was added a
suspension of NaH (300 mg, 12.5 mmol) in THF (6.4 mL) dropwise
under Ar. The reaction mixture was stirred at rt for 12 before
quenching with a mixture of acetic acid (1.2 g, 20 mmol) and H2O (1
mL). Solvent removal in vacuo gave a crude product which was
crystallized from hexane to aﬀord 31 as a white solid (406 mg, 52%).
mp 217−219 °C; 1H NMR (DMSO-d6) δ 1.36 (s, 6H), 7.46 (dd, J =
10.8, 8.9 Hz, 1H), 7.83 (s, 1H), 8.30−8.40 (m, 1H), 8.47 (dd, J = 7.4,
2.2 Hz, 1H), 11.68 (s, 1H). 13C NMR (DMSO-d6) δ 24.54, 56.49,
98.64, 115.88 (qd, J = 31.8, 12.2 Hz), 116.56 (d, J = 20.1 Hz), 122.87
(q, J = 271.4 Hz), 124.55 (q, J = 4.8 Hz), 129.75 (d, J = 3.7 Hz),
132.87 (d, J = 8.0 Hz), 156.37 (d, J = 250.9 Hz), 170.39, 176.13. Anal.
Calcd for C13H11F4NO2: C, 53.99; H, 3.83; N, 4.84. Found: C, 54.09;
H, 3.92; N, 4.60.
1-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-4,4-dimethylimidazolidin-
2-one (32). To a solution of 4,4-dimethyl-2-imidazolidinone (48)
(500 mg, 4.4 mmol), Cs2CO3 (2.460 g, 7.5 mmol), Xantphos (108 mg,
0.19 mmol), and Pd2(dba)3 (84 mg, 0.09 mmol) in toluene (40 mL)
was added 1-ﬂuoro-4-iodo-2-(triﬂuoromethyl)benzene (45) (1.270 g,
4.4 mmol). The reaction mixture was stirred at 90 °C for 12 h under
Ar. Evaporation gave a crude product which was puriﬁed by washing
with water (25 mL), chromatography (sg, EtOAc), and recrystallizion
from hexane to aﬀord 32 as a white solid (939 mg, 77%). mp 147−148
°C; 1H NMR (DMSO-d6) δ 1.28 (s, 6H), 3.64 (s, 2H), 7.39 (s, 1H),
7.45 (t, J = 9.8 Hz, 1H), 7.72 (dt, J = 9.2, 3.6 Hz, 1H), 8.05 (dd, J =
6.4, 2.9 Hz, 1H); 13C NMR (DMSO-d6) δ 28.20, 50.57, 57.07, 114.69
(q, J = 5.2 Hz), 116.22 (qd, J = 32.1, 12.9 Hz), 117.29 (d, J = 21.3 Hz),
122.30 (d, J = 7.7 Hz), 122.66 (q, J = 272.3 Hz), 137.58, 153.26 (d, J =
247.5 Hz), 157.02. Anal. Calcd for C12H12F4N2O: C, 52.18; H, 4.38;
N, 10.14. Found: C, 52.32; H, 4.57; N, 10.26.
1-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5,5-dimethylimidazoli-
dine-2,4-dione (33). Step 1. To a mixture of 4-ﬂuoro-3-
(triﬂuoromethyl)aniline (63) (1.791 g, 10 mmol), formamide (50
mL), and acetone (25 mL) was added 1 M TiCl4 in CH2Cl2 (12.5 mL)
at 0 °C under Ar. After 1 h, Zn powder (1.5 g, 23 mmol) was added
followed by dropwise addition of 50% H2O2 (1.75 mL) in formamide
(23.25 mL) over 3 h. The reaction was quenched with H2O (25 mL),
and the pH adjusted to 8 with concentrated ammonium hydroxide
followed by extraction with EtOAc (3 × 50 mL). The combined
organic layers were concentrated in vacuo, and the residue was
dissolved in CHCl3 (100 mL). The solution was then washed with
H2O (3 × 25 mL). Evaporation gave a crude product which was
further puriﬁed by successive recrystallizations from a mixture of
CH2Cl2 (5 mL) and hexane (1 mL) and a mixture of acetic acid (150
mg) and H2O (1 mL) to aﬀord 2-[[4-ﬂuoro-3-(triﬂuoromethyl)-
phenyl]amino]-2-methylpropanamide (66) as a white solid (418 mg,
16%); 1H NMR (DMSO-d6) δ 1.35 (s, 6H), 6.18 (s, 1H), 6.71 (dt, J =
9.0, 3.6 Hz, 1H), 6.81 (dd, J = 6.0, 3.0 Hz, 1H), 7.05 (s, 1H), 7.22 (t, J
= 9.8 Hz, 1H), 7.34 (s, 1H). 13C NMR (DMSO-d6) δ 25.22, 56.63,
111.09 (q, J = 4.7 Hz), 116.20 (qd, J = 31.5, 13.0 Hz), 117.16 (d, J =
21.2 Hz), 118.79 (d, J = 7.4 Hz), 122.92 (q, J = 272.0 Hz), 143.20 (d, J
= 1.9 Hz), 150.44 (dq, J = 241.0, 2.4 Hz), 177.13. Step 2. To a
solution of 66 (160 mg, 0.6 mmol) in toluene (5 mL) was added 2-
isocyanato-1,3-diisopropylbenzene (143 mg, 0.7 mmol). After the
mixture was heated to 250 °C at 5 bar for 10 min under microwave
irradiation in a sealed tube, the solvent was evaporated in vacuo. The
residue was puriﬁed by sg chromatography eluting successively with
CH2Cl2 and 1:3 acetone:hexane to aﬀord 33 as a white solid (108 mg,
62%). mp 193−195 °C; 1H NMR (DMSO-d6) δ 1.34 (s, 6H), 7.63 (t,
J = 9.7 Hz, 1H), 7.71−7.78 (m, 1H), 7.84 (dd, J = 6.6, 2.6 Hz, 1H),
11.26 (s, 1H); 13C NMR (DMSO-d6) δ 23.09, 64.21, 117.25 (qd, J =
32.8, 13.2 Hz), 118.25 (d, J = 21.5 Hz), 122.18 (q, J = 273.5 Hz),
128.19, 131.44 (d, J = 3.4 Hz), 135.86 (d, J = 9.2 Hz), 154.99, 157.87
(d, J = 254.8 Hz), 177.14. Anal. Calcd for C12H10F4N2O2: C, 49.66; H,
3.47; N, 9.65. Found: C, 49.71, H, 3.58, N, 9.80.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-6,6-dimethyldihydropyri-
midine-2,4(1H,3H)-dione (34). Step 1. To a solution of 3-amino-3-
methylbutanoic acid (61) (585 mg, 5.0 mmol) in 2 M NaOH (5 mL)
was added 56 (1.95 g, 9.5 mmol). After it was stirred at rt for 4 h, the
reaction mixture was ﬁltered to remove the insoluble N,N-diarylurea
side product, and the ﬁltrate was adjusted to pH 1.0 with 2 M HCl and
concentrated. Step 2. The residue was suspended in 2 M HCl (50 mL)
and then heated at 110 °C for 2 h. After the reaction mixture was
cooled to rt, the resulting precipitate was ﬁltered and washed with
H2O (20 mL) to give 34 as a white solid (477 mg, 31%). mp 225−226
°C; 1H NMR (DMSO-d6) δ 1.31 (s, 6H), 2.74 (s, 2H), 7.53−7.64 (m,
2H), 7.71 (dd, J = 6.7, 2.4 Hz, 1H), 8.18 (s, 1H);13C NMR (DMSO-
d6) δ 28.11, 44.32, 48.22, 116.88 (qd, J = 32.6, 13.3 Hz), 117.68 (d, J =
21.5 Hz), 122.54 (q, J = 272.3 Hz), 128.60 (d, J = 4.8 Hz), 132.82 (d, J
= 3.5 Hz), 136.61 (d, J = 9.1 Hz), 152.51, 158.16 (d, J = 254.0 Hz),
169.81. Anal. Calcd for C13H12F4N2O2 0.5 H2O: C, 49.85; H, 4.18; N,
8.94. Found: C, 49.79; H, 4.51; N, 8.81.
3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]-5,5-dimethyldihydropyri-
midine-2,4(1H,3H)-dione (35). Step 1. To a solution of 3-amino-2,2-
dimethylpropanoic acid hydrochloride (62) (700 mg, 4.6 mmol) in 2
M NaOH (5 mL) was added 56 (1.95 g, 9.5 mmol), and the reaction
mixture was stirred at rt for 4 h. After ﬁltration to remove the insoluble
N,N-diarylurea side product, the ﬁltrate was adjusted to pH 1.0 with 2
M HCl and concentrated to aﬀord 3-[3-[4-ﬂuoro-3-(triﬂuoromethyl)-
phenyl]ureido]-2,2-dimethylpropanoic acid (480 mg, 32%) as a white
solid. 1H NMR (DMSO-d6) δ 1.09 (s, 6H), 3.22 (d, J = 6.2 Hz, 2H),
6.25 (t, J = 6.2 Hz, 1H), 7.36 (t, J = 9.8 Hz, 1H), 7.43−7.53 (m, 1H),
7.95 (dd, J = 6.5, 2.8 Hz, 1H), 8.99 (s, 1H), 12.39 (s, 1H). Step 2. 3-
[3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]ureido]-2,2-dimethylpropa-
noic acid (450 mg, 1.4 mmol) was suspended in 2 M HCl (50 mL)
and then heated at 110 °C for 12 h. After the reaction mixture was
cooled to rt, the resulting precipitate was ﬁltered and washed with
saturated NaHCO3 (30 mL) to give 35 as a white solid (355 mg,
83%). mp 214−215 °C; 1H NMR (DMSO-d6) δ 1.21 (s, 6H), 3.18 (s,
1H), 3.18 (d, J = 2.8 Hz, 1H), 7.52−7.59 (m, 2H), 7.63−7.69 (m,
1H), 8.11 (s, 1H); 13C NMR (DMSO-d6) δ 22.35, 37.39, 46.31,
116.60 (qd, J = 32.9, 13.7 Hz), 117.41 (d, J = 21.5 Hz), 122.34 (q, J =
271.9 Hz), 128.34, 133.07 (d, J = 3.5 Hz), 136.42 (d, J = 9.2 Hz),
153.02, 157.88 (d, J = 253.6 Hz), 175.33. Anal. Calcd for
C13H12F4N2O2: C, 51.32; H, 3.98; N, 9.21. Found: C, 51.19; H,
3.99; N, 9.12.
2-[3-[4-Fluoro-3-(triﬂuoromethyl)phenyl]ureido]-2-methylpropa-
noic acid (36). Hydantoin 1 (1.20 g, 4.1 mmol) was added to 2 M
NaOH (40 mL). The reaction mixture was stirred at rt for 4 h, and
then quenched with 2 M HCl (50 mL). The precipitate was ﬁltered
and rinsed with H2O (20 mL) and then dried to aﬀord 36 as a white
solid (1.20 g, 95%). mp 196.5−197.5 °C; 1H NMR (DMSO-d6) δ 1.43
(s, 6H), 6.61 (s, 1H), 7.37 (t, J = 9.8 Hz, 1H), 7.47−7.50 (m,1H),
7.96−7.97 (m, 1H), 8.87 (s, 1H), 12.44 (s, 1H); 13C NMR (DMSO-
d6) δ 25.42, 55.13, 115.12 (d, J = 5.0 Hz), 116.45 (qd, J = 31.6, 12.8
Hz), 117.65 (d, J = 21.5 Hz), 122.85 (q, J = 272.1 Hz), 123.42 (d, J =
7.8 Hz), 137.34, 153.32 (d, J = 246.9 Hz), 154.37, 176.31. Anal. Calcd
for C12H12F4N2O3: C, 46.76; H, 3.92; N, 9.09. Found: C, 46.50; H,
4.04; N, 9.19.
Polar Surface Area (PSA). PSA values (Å2) were calculated using
ChemAxon Instant JChem (ver 16.4).
Kinetic Solubility. Compounds in DMSO (10 mg/mL) were
diluted into either pH 6.5 phosphate buﬀer or 0.01 M HCl
(approximately pH 2.0), with the ﬁnal DMSO concentration being
1%. Samples were then analyzed via nephelometry to determine a
solubility range.45
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Partition Coeﬃcient. Partition coeﬃcient values (Log D) of the
test compounds were estimated by correlation of their chromato-
graphic retention properties against the characteristics of a series of
standard compounds with known partition coeﬃcient values using
gradient HPLC (modiﬁcation of a method reported by Lombardo et
al.46
Plasma Protein Binding. Plasma protein binding values of the
test compounds were estimated by correlation of their chromato-
graphic retention properties on a human albumin column against the
characteristics of a series of standard compounds with known protein
binding values. The method employed is a gradient HPLC based
derivation of the method developed by Valko et al.47
In Vitro Metabolic Stability. Metabolic stability assays were
performed by incubating test compounds in liver microsomes at 37 °C
and 0.4 mg/mL protein concentration. The metabolic reaction was
initiated by the addition of an NADPH-regenerating system and
quenched at various time points over a 60 min incubation period by
the addition of acetonitrile containing diazepam as internal standard.
Control samples (containing no NADPH) were included (and
quenched at 2, 30, and 60 min) to monitor for potential degradation
in the absence of cofactor. Compound concentrations were
determined by LC/MS by comparison to calibration standards
prepared in prequenched microsomal matrix.
Mouse Exposure Studies. Pharmacokinetic studies in mice were
conducted at Monash University, Parkville, Australia, and were
performed in accordance with the Australian Code of Practice for
the Care and Use of Animals for Scientiﬁc Purposes. The study
protocol adhered to the principles of reduction, reﬁnement, and
replacement and was approved by the Monash Institute of
Pharmaceutical Sciences Animal Ethics Committee. The systemic
exposure of the aryl hydantoins was studied in nonfasted male Swiss
outbred mice weighing 25−33 g (7 mice per compound). Mice had
access to food and water ad libitum throughout the pre- and postdose
sampling period. Formulations were prepared by dispersing the aryl
hydantoins in Tween 80 and then adding ethanol and Milli-Q water
(ﬁnal composition 7% v/v Tween 80, 3% v/v ethanol). Following
vortexing and sonication, samples formed either uniform suspensions
(1−3, 14, 16, 23, 26) or a colorless solution (13). Compound
formulations were mixed by inverting the tubes prior to drawing each
dosing volume. All animals were dosed orally by gavage (10 mL/kg
dose volume) within 1 h of formulation preparation. Following
administration, blood samples were collected from 0.25 to 48 h
postdose (n = 2 mice per time point). A maximum of two samples
were obtained from each mouse, with samples being taken either via
submandibular bleed (approximately 120 μL; conscious sampling) or
terminal cardiac puncture (0.6 mL; while mice were under deep
anesthesia using inhaled isoﬂurane). No urine samples were collected,
as mice were housed in bedded cages during the study. Blood was
collected directly into polypropylene Eppendorf tubes containing
heparin as anticoagulant and stabilization cocktail (containing
Complete (a protease inhibitor cocktail), potassium ﬂuoride, and
EDTA) to minimize the potential for ex vivo degradation of the aryl
hydantoins in blood/plasma samples. Once collected, blood samples
were centrifuged immediately, and supernatant plasma was removed
and stored at −80 °C until analysis by LCMS. Plasma concentrations
were determined by comparison to calibration standards prepared in
blank plasma and treated the same as the plasma samples. Plasma
concentration−time data were analyzed using noncompartmental
methods (PKSolver Version 2.0).
S. mansoni in Vivo Studies. The in vivo study was approved by
the local veterinary agency, based on Swiss cantonal and national
regulations (permission no. 2070). As described by Keiser,48 cercariae
of S. mansoni were obtained from infected Biomphalaria glabrata.
NMRI mice were infected subcutaneously with approximately 100 S.
mansoni cercariae. At 49 d after infection, groups of four mice were
treated with single 100 mg/kg oral doses of compounds in a 7% (v/v)
Tween 80% and 3% (v/v) ethanol vehicle (10 mL/kg). Untreated
mice (n = 8) served as controls. At 21 d post-treatment, animals were
killed by the CO2 method and dissected. Worms were removed by
picking, then sexed and counted.
Androgen-Dependent Cell-Based Assay. As described by Jones
and Diamond,49 LAPC4 cells were cultured in phenol red free RPMI
1640 media supplemented with antibiotics and 10% FBS. For all
transfections, pools of cells were transfected using Lipofectamine Plus
(Invitrogen) with PSA-luciferase50 and pRL-SV40 (Promega) as a
normalization control. The following day, the cells were replated, 0.3
nM DHT and test compounds were added, and 24 h later luciferase
production was measured (Dual luciferase assay kit; Promega),
normalizing the ﬁreﬂy signal to the renilla signal. Mean-eﬀect plots
(log[compound] vs log[fractional eﬀect]) were generated to
determine the IC50 values for each test compound or combinations
of test compounds at constant ratios.
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(33) Hügel, H. M.; Rix, C. J.; Fleck, K. Comparison of copper(II)
acetate promoted N-arylation of 5,5-dimethylhydantoin and other
imides with triarylbismuthanes and arylboronic acids. Synlett 2006, 14,
2290−2292.
(34) Lan, J.; Zhang, G.; Yu, X.; You, J.; Chen, L.; Yan, M.; Xie, R. A
simple copper salt catalyzed N-arylation of amines, amides, imides, and
sulfonamides with arylboronic acids. Synlett 2004, 35, 1095−1097.
(35) Chan, D. M.; Monaco, K. L.; Wang, R.-P.; Winters, M. P. New
N-and O-arylations with phenylboronic acids and cupric acetate.
Tetrahedron Lett. 1998, 39, 2933−2936.
(36) Hroch, L.; Hruskova,́ M.; Schmitz, J.; Schnakenburg, G.;
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Malagueño, E.; Santana, J. V.; Lima, M. C.; Galdino, S. L.; Pitta, I. R.;
Albuquerque, M. C. New imidazolidinic bioisosters: Potential
candidates for antischistosomal drugs. Mem. Inst. Oswaldo Cruz.
2006, 101, 313−316.
(43) da Silva, A. C.; Neves, J. K.; Irmaõ, J. I.; Costa, V. M.; Souza, V.
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